Share information
276.80 €
+2.33 %
29/10/2026 10:05
+2.33 %
Open
High
Low
Volume
270.80 €
277.70 €
270.80 €
19,335
Latest News
22-Oct-2026
Strong Performance Drives Further Upgrade to UCB’s 2026 Financial Guidance
19-Oct-2026
Transparency notification Wellington
16-Oct-2026
UCB announces U.S. FDA approval for ZILBRYSQ[®] (zilucoplan) autoinjector self-administration for adults living with generalized myasthenia gravis
30-Sep-2026
UCB announces new data at EADV 2026 supporting earlier use of BIMZELX[®] (bimekizumab) for treating hidradenitis suppurativa